Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345188 · ClinicalTrials.gov registry record · Phase 4
Ranolazine in Ischemic Cardiomyopathy
A Phase 4 study, sponsored by Midwest Cardiovascular Research Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT01345188 is a Phase 4 study that has completed, run by Midwest Cardiovascular Research Foundation. The registered enrollment target is 28 participants.
The verdict
NCT01345188, a Phase 4 study, has completed, sponsored by Midwest Cardiovascular Research Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.
Interventions
- DRUG Placebo
- DRUG Ranexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345188
The ClinicalTrials.gov registry entry for NCT01345188 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midwest Cardiovascular Research Foundation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01345188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345188 about?
NCT01345188 is a clinical study titled "Ranolazine in Ischemic Cardiomyopathy". Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to block...
What is the current status of trial NCT01345188?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2011-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01345188?
The interventions under investigation include: Placebo (DRUG), Ranexa (DRUG).
Who is sponsoring clinical trial NCT01345188?
This trial is sponsored by Midwest Cardiovascular Research Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.